Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro)

• ClinicalTrials.gov Identifier: NCT00296790
• Recruitment Status: Completed
• First Posted: February 27, 2006
• Last Update Posted: October 12, 2007
• Sponsor: Sanofi
• Information provided by: Sanofi

Study Description

Brief Summary:

A comparison of Zolpidem Tartrate Extended-Release (Ambien CR)vs. Placebo in the Treatment of Insomnia Associated with Generalized Anxiety Disorder (GAD) when Used Concomitantly with Escitalopram (Lexapro - antidepressant).

Condition or disease	Intervention/treatment	Phase
Insomnia	Drug: zolpidem tartrate	Phase 4

Study Design

• Study Type: Interventional (Clinical Trial)
• Enrollment: 372 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double
• Primary Purpose: Treatment
• Study Start Date: February 2006
• Study Completion Date: February 2007

Arms and Interventions

Outcome Measures

Primary Outcome Measures :

1. Evaluate safety and hypnotic efficacy of zolpidem tartrate extended release vs. placebo in treatment of insomnia associated with Generalized Anxiety Disorder when used concomitantly with escitalopram

Secondary Outcome Measures :

1. To show that treating insomnia from beginning of SSRI (Selective Serotonin Reuptake Inhibitor) treatment for anxiety results in improvement in quality of life and possibly greater response to anti-anxiety therapy

Eligibility Criteria

• Ages Eligible for Study: 21 Years to 64 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

INCLUSION CRITERIA:

1. Male or female between the ages of 21and 64 years, inclusive;
2. Women must use a medically acceptable form of contraception during the entire study period, or: be surgically sterilized, post-menopausal, agree to use double-barrier contraception throughout the study period, or must have a negative urine pregnancy test prior to randomization;
3. Must meet the diagnostic requirements of Generalized Anxiety Disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders;
4. Score at least 18 on the Hamilton Rating Scale for Anxiety (HAM-A)
5. Must be either newly diagnosed or show symptoms of relapse during a period of no drug therapy for anxiety.
6. Subject must experience sleep disturbances at least three nights per week, for at least one month prior to study entry, based on historical data.
7. Subject must be stabilized on all long-term medication therapy for at least one month prior to study entry.

EXCLUSION

1. History of Post-Traumatic Stress Disorder;
2. Concomitant Major Depressive Disorder or Bipolar Disorder;
3. Any abnormal pre-study laboratory values that require clinical intervention
4. Shift work or requirement for a regular change in sleep schedule by at least six hours within the previous month.
5. Pregnant or breastfeeding
6. History of drug addiction, alcoholism, or drug abuse
7. Currently using a benzodiazepine or SSRI or more than 2 days of use within the 28 days preceding randomization.
8. A positive urine drug screen for compounds that would interfere with the assessment of a hypnotic.
9. Use of prescription and non-prescription sedative drugs;
10. Prior failure to respond to escitalopram therapy for anxiety
11. The presence of any untreated or uncompensated clinically significant renal, endocrine, gastrointestinal, hepatic, respiratory, cardiovascular, other neurologic, hematologic, oncologic, immunologic, cerebrovascular disease or malignancy.
12. History of sleep apnea
13. History of myasthenia gravis
14. Known hypersensitivity and/or allergy to or previous adverse experience with zolpidem or escitalopram or any of their excipients
15. Subject is currently participating in another clinical trial (or within 28 days of screening).

Contacts and Locations

Locations

United States, New Jersey

Sanofi-Aventis

Bridgewater, New Jersey, United States, 08807

Sponsors and Collaborators

Sanofi

Investigators

• Study Director: Phyllis Diener; Sanofi

More Information

• ClinicalTrials.gov Identifier: NCT00296790
• Other Study ID Numbers: PM_L_0167
• First Posted: February 27, 2006
• Last Update Posted: October 12, 2007
• Last Verified: October 2007

Additional relevant MeSH terms:

Sleep Initiation and Maintenance Disorders; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Nervous System Diseases; Mental Disorders; Zolpidem; Sleep Aids, Pharmaceutical; Hypnotics and Sedatives; Central Nervous System Depressants; Physiological Effects of Drugs; GABA-A Receptor Agonists; GABA Agonists; GABA Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action